Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis

The COVID-19 pandemic is caused by the SARS CoV-2 virus and can lead to severe lung damage and hyperinflammation. In the context of COVID-19 infection, inflammation-induced degradation of the glycocalyx layer in endothelial cells has been demonstrated. Syndecan-1 (SDC-1) is an established parameter...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Richard Vollenberg, Phil-Robin Tepasse, Kevin Ochs, Martin Floer, Markus Strauss, Florian Rennebaum, Iyad Kabar, Alexandros Rovas, Tobias Nowacki
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	SARS-CoV-2 COVID-19 syndecan-1 glycocalyx long-COVID-19 Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/8a37347b50894411b5e0478c0ef79181
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8a37347b50894411b5e0478c0ef79181
record_format	dspace
spelling	oai:doaj.org-article:8a37347b50894411b5e0478c0ef791812021-11-25T19:14:35ZIndications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis10.3390/v131123241999-4915https://doaj.org/article/8a37347b50894411b5e0478c0ef791812021-11-01T00:00:00Zhttps://www.mdpi.com/1999-4915/13/11/2324https://doaj.org/toc/1999-4915The COVID-19 pandemic is caused by the SARS CoV-2 virus and can lead to severe lung damage and hyperinflammation. In the context of COVID-19 infection, inflammation-induced degradation of the glycocalyx layer in endothelial cells has been demonstrated. Syndecan-1 (SDC-1) is an established parameter for measuring glycocalyx injury. This prospective, multicenter, observational, cross-sectional study analyzed SDC-1 levels in 24 convalescent patients that had been infected with SARS-CoV-2 with mild disease course without need of hospitalization. We included 13 age-matched healthy individuals and 10 age-matched hospitalized COVID-19 patients with acute mild disease course as controls. In convalescent COVID-19 patients, significantly elevated SDC-1 levels were detected after a median of 88 days after symptom onset compared to healthy controls, whereas no difference was found when compared to SDC-1 levels of hospitalized patients undergoing acute disease. This study is the first to demonstrate signs of endothelial damage in non-pre-diseased, convalescent COVID-19 patients after mild disease progression without hospitalization. The data are consistent with studies showing evidence of persistent endothelial damage after severe or critical disease progression. Further work to investigate endothelial damage in convalescent COVID-19 patients should follow.Richard VollenbergPhil-Robin TepasseKevin OchsMartin FloerMarkus StraussFlorian RennebaumIyad KabarAlexandros RovasTobias NowackiMDPI AGarticleSARS-CoV-2COVID-19syndecan-1glycocalyxlong-COVID-19MicrobiologyQR1-502ENViruses, Vol 13, Iss 2324, p 2324 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	SARS-CoV-2 COVID-19 syndecan-1 glycocalyx long-COVID-19 Microbiology QR1-502
spellingShingle	SARS-CoV-2 COVID-19 syndecan-1 glycocalyx long-COVID-19 Microbiology QR1-502 Richard Vollenberg Phil-Robin Tepasse Kevin Ochs Martin Floer Markus Strauss Florian Rennebaum Iyad Kabar Alexandros Rovas Tobias Nowacki Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis
description	The COVID-19 pandemic is caused by the SARS CoV-2 virus and can lead to severe lung damage and hyperinflammation. In the context of COVID-19 infection, inflammation-induced degradation of the glycocalyx layer in endothelial cells has been demonstrated. Syndecan-1 (SDC-1) is an established parameter for measuring glycocalyx injury. This prospective, multicenter, observational, cross-sectional study analyzed SDC-1 levels in 24 convalescent patients that had been infected with SARS-CoV-2 with mild disease course without need of hospitalization. We included 13 age-matched healthy individuals and 10 age-matched hospitalized COVID-19 patients with acute mild disease course as controls. In convalescent COVID-19 patients, significantly elevated SDC-1 levels were detected after a median of 88 days after symptom onset compared to healthy controls, whereas no difference was found when compared to SDC-1 levels of hospitalized patients undergoing acute disease. This study is the first to demonstrate signs of endothelial damage in non-pre-diseased, convalescent COVID-19 patients after mild disease progression without hospitalization. The data are consistent with studies showing evidence of persistent endothelial damage after severe or critical disease progression. Further work to investigate endothelial damage in convalescent COVID-19 patients should follow.
format	article
author	Richard Vollenberg Phil-Robin Tepasse Kevin Ochs Martin Floer Markus Strauss Florian Rennebaum Iyad Kabar Alexandros Rovas Tobias Nowacki
author_facet	Richard Vollenberg Phil-Robin Tepasse Kevin Ochs Martin Floer Markus Strauss Florian Rennebaum Iyad Kabar Alexandros Rovas Tobias Nowacki
author_sort	Richard Vollenberg
title	Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis
title_short	Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis
title_full	Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis
title_fullStr	Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis
title_full_unstemmed	Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis
title_sort	indications of persistent glycocalyx damage in convalescent covid-19 patients: a prospective multicenter study and hypothesis
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/8a37347b50894411b5e0478c0ef79181
work_keys_str_mv	AT richardvollenberg indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis AT philrobintepasse indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis AT kevinochs indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis AT martinfloer indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis AT markusstrauss indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis AT florianrennebaum indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis AT iyadkabar indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis AT alexandrosrovas indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis AT tobiasnowacki indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis
_version_	1718410104024334336

Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis

Ejemplares similares